NCT06321510Completed
A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
REAL-WORLD TREATMENT PATTERNS AND CLINICAL EFFECTIVENESS OF DACOMITINIB IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR-POSITIVE IN TAIWAN
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer. This study is seeking participants who: * have lung cancer that could not be controlled. * have a type of gene called epidermoid growth factor receptor. A gene is a part of your DNA that has instructions for making things your body needs to work. * have received dacomitinib for their lung cancer. All participants in this study had received dacomitinib. Dacomitinib is a tablet that is taken by mouth at home. They continued to take dacomitnib until their cancer was no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 29 (actual)
- First submitted
- 13 Mar 2024
- Start date
- 1 Jul 2024
- Primary completion date
- 19 Sept 2025
- Lead sponsor
- Pfizer
- Diseases
- Lung cancer
- NCT number
- NCT06321510
What you commit to
- Study type: Observational
- Participants enrolled: 29
- From 1 Jul 2024 to the primary completion date, 19 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have been treated with any systemic anti-cancer therapies within 12 months prior to dacomitinib treatment.
Who the study is looking for
- Evidence of histologically or cytologically confirmed diagnosis of advanced NSCLC with EGFR-activating mutations detected by an appropriate test
- Patients who were treated with dacomitinib as first-line treatment for advanced NSCLC during 01 October 2020 to 31 December 2022.
- Age ≥18 years old
- Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tri-Service General Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.